Commentary
Video
Author(s):
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the sensitivity and specificity of Rapid Lung NGS for biomarker testing in NSCLC.
Revumenib Meets CR/CRh End Point in NPM1+ R/R AML
Ongoing Research Advances Equity and Precision Oncology Through Tissue-Agnostic Therapies: With Chandler Park, MD, and Vivek Subbiah, MD
Personalized Initiatives Empower Patients to Actively Participate in Cancer Research
How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD
THIO Plus Cemiplimab Displays Efficacy in Checkpoint Inhibitor–Resistant NSCLC
Frontline Vibostolimab/Pembrolizumab Plus Chemo Meets Futility Threshold in ES-SCLC
RP1 Plus Nivolumab Is Active, Safe in Advanced Melanoma After Progression on Anti–PD-1 Therapy
IMA203 Produces Responses in Heavily Pretreated Advanced Melanoma, Other Solid Tumors
Invikafusp Alfa Demonstrates Single-Agent Activity in PD-(L)1–Resistant Solid Tumors
Temozolomide/Pembrolizumab Plus TTFields Leads to Tumor Control in Newly Diagnosed Glioblastoma